Eversept Partners LP Purchases Shares of 48,241 Ascendis Pharma A/S $ASND

Eversept Partners LP acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 48,241 shares of the biotechnology company’s stock, valued at approximately $10,287,000.

Other hedge funds also recently made changes to their positions in the company. Advisory Services Network LLC bought a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at approximately $26,000. Arax Advisory Partners grew its stake in shares of Ascendis Pharma A/S by 212.2% during the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 104 shares during the period. Leonteq Securities AG bought a new position in shares of Ascendis Pharma A/S during the 4th quarter valued at approximately $36,000. Global Retirement Partners LLC grew its stake in shares of Ascendis Pharma A/S by 111.9% during the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 113 shares during the period. Finally, GW&K Investment Management LLC grew its stake in shares of Ascendis Pharma A/S by 75.2% during the 4th quarter. GW&K Investment Management LLC now owns 226 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 97 shares during the period.

Ascendis Pharma A/S Stock Down 0.0%

NASDAQ ASND opened at $231.15 on Thursday. The stock’s 50 day moving average is $232.16 and its 200 day moving average is $224.09. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. Ascendis Pharma A/S has a 12 month low of $160.86 and a 12 month high of $250.74. The stock has a market cap of $14.42 billion, a PE ratio of 26.66 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The business had revenue of $285.45 million during the quarter, compared to analysts’ expectations of $362.47 million. Research analysts predict that Ascendis Pharma A/S will post 14.25 EPS for the current fiscal year.

Insider Buying and Selling

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime purchased 400 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were bought at an average cost of $237.80 per share, with a total value of $95,120.00. Following the acquisition, the director owned 400 shares in the company, valued at approximately $95,120. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The SEC filing for this sale provides additional information. 40.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ASND. Oppenheimer reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Tuesday, June 9th. Wells Fargo & Company cut their price objective on Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Jefferies Financial Group began coverage on Ascendis Pharma A/S in a research note on Monday, March 16th. They set a “buy” rating and a $290.00 price objective for the company. Evercore reiterated an “outperform” rating and set a $329.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $255.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $295.39.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.